论文部分内容阅读
对绝经后妇女应用小剂量利维爱为期 3年的前瞻性研究。服药剂量每日 1 .2 5mg (1 / 2量组 ) 3 9例和每日 0 .62 5 mg (1 / 4量组 ) 1 2例。于用药前及用药后每 6个月随诊 ,分别观察骨密度、尿 Ca/ Cr比值、血脂 ,子宫大小、子宫内膜厚度 ,体重及副反应等。结果 :两组经 SPA、DXA和 QCT测量骨密度均有上升。以 QCT更为明显 ,其中 1 / 2量组治疗后上升 1 5 .4% ,与治疗前相比有显著差异 (P<0 .0 0 1 ) ,1 / 4量组治疗后上升 9.0 % ,与治疗前相比无显著差异 (P>0 .0 5 ) ;两组尿 Ca/ Cr比值相应的下降率分别为 1 1 .8%与8.6%。两组甘油三脂相应下降 1 6.5 %和 2 6.7% ;两组子宫内膜厚度虽有所增加 ,但平均厚度均未超过 0 .5 cm。以上各项两组相比均无显著差异 (P>0 .0 5 )。阴道出血率 2 6%(1 3 / 5 1 ) ,其中 77% (1 0 / 1 3 )为绝经 3年内开始服药 ,63 % (8/ 1 3 )为服药 1年内开始出血。体重在 1 / 2量组增加约 5 %而 1 / 4量组无明显增加 ,但两组相比也无明显差异 (P>0 .0 5 )。结论 :绝经后妇女应用 1 / 2量利维爱可提高骨密度 ,1 / 4量利维爱可维持骨量 ;甘油三脂均下降 ,参与保护心血管的作用 ,对子宫内膜无明显刺激作用。结果显示利维爱能有效地用于绝经后妇女激素替代治疗 ,但例数较少 ,年龄段有?
A 3-year, prospective, long-term, low-dose Levi care for postmenopausal women. The daily dose was 12.5 mg (1/2 dose) and 12 patients (0.56 mg / day) daily. Bone mineral density, urinary Ca / Cr ratio, blood lipids, uterine size, endometrial thickness, body weight and side effects were observed before treatment and every 6 months after treatment. RESULTS: Bone mineral density was increased in both groups by SPA, DXA, and QCT. QCT was more obvious, of which 1/2 dose group increased by 15.4% after treatment, which was significantly different from that before treatment (P <0. 001), while the 1/4 dose group increased by 9.0% There was no significant difference between before and after treatment (P> 0.05). The corresponding rate of decrease of urinary Ca / Cr ratio was 11.8% and 8.6% respectively. The two groups of triglycerides decreased by 1 6.5% and 2 6.7%, respectively. Although the endometrial thickness of the two groups increased, the mean thickness did not exceed 0.5 cm. There was no significant difference between the above two groups (P> 0.05). Vaginal bleeding rate was 26% (13/51), of which 77% (10/13) started to be taken within 3 years of menopause and 63% (8/1 3) started bleeding within 1 year after taking the medicine. Body weight increased by about 5% in 1/2 dose group and no significant increase in 1/4 dose group, but there was no significant difference between the two groups (P> 0.05). CONCLUSIONS: 1/2 dose of Levi in postmenopausal women increased bone mineral density and 1/4 dose of Levofloxacin maintained the bone mass. Both triglycerides decreased and they were involved in the protection of cardiovascular function without significant stimulation of the endometrium effect. The results show that Levi can effectively be used for hormone replacement therapy in postmenopausal women, but fewer cases, age groups?